The Valley Desk

NCT02030834 · Interventional trial

Phase IIa Study of Redirected Autologous T Cells Engineered to Contain Anti-CD19 Attached to TCRz and 4-Signaling Domains in Patients With Chemotherapy Relapsed or Refractory CD19+ Lymphomas

Overall registry status Completed

Phase 2

Conditions Non-Hodgkins Lymphoma (NHL) Patients, With CD19+B Cell Lymphomas

Delaware Valley sites

First posted

Registry updated

Added to the directory

View this study on ClinicalTrials.gov